Abstract
Myotonic dystrophy type 1 (DM1) is a rare, genetic, progressive muscle disease associated with high morbidity and premature mortality for which there are no available disease-modifying therapies. Current treatment focuses on managing symptoms and minimizing disability, resulting in substantial disease burden. The objective of this literature review was to understand the burden that DM1 has on the overall quality of life (QoL) of affected individuals.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
